Human Immunodeficiency Virus—Related Oral Manifestations and Gender

1996 ◽  
Vol 156 (19) ◽  
pp. 2249 ◽  
Author(s):  
Caroline H. Shiboski
Keyword(s):  
Human Immunodeficiency Virus ◽  
Oral Manifestations ◽  
Immunodeficiency Virus ◽  
And Gender

scholarly journals Steady-State Pharmacokinetics of Abacavir in Plasma and Intracellular Carbovir Triphosphate following Administration of Abacavir at 600 Milligrams Once Daily and 300 Milligrams Twice Daily in Human Immunodeficiency Virus-Infected Subjects

2009 ◽  
Vol 53 (4) ◽  
pp. 1532-1538 ◽  
Author(s):  
Graeme Moyle ◽  
Marta Boffito ◽  
Carl Fletcher ◽  
Chris Higgs ◽  
Phillip E. Hay ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
High Performance ◽  
Pharmacokinetic Parameters ◽  
Virologic Suppression ◽  
Open Label ◽  
Time Curve ◽  
Mixed Effect ◽  
Once Daily ◽  
Immunodeficiency Virus ◽  
And Gender

ABSTRACT Abacavir (ABC) is administered either at 600 mg once daily (ABC 600 mg QD) or 300 mg twice daily (ABC 300 mg BID) in anti-human immunodeficiency virus (anti-HIV) combination therapy. Although ABC plasma pharmacokinetics following each regimen has been well defined, no study has directly compared the regimens with respect to pharmacokinetics of ABC's active intracellular anabolite, carbovir-triphosphate (CBV-TP). In an open-label, two-period, crossover study, 34 HIV-infected male and female subjects stabilized on antiretroviral regimens containing either ABC 600 mg QD or ABC 300 mg BID received their usual doses on days −1 and 1 and then switched regimens for days 2 to 11. Serial blood samples collected on days 1 and 11 were assayed for plasma ABC and intracellular CBV-TP concentrations using validated high-performance liquid chromatography-tandem mass spectrometry methods. Pharmacokinetic parameters were calculated using noncompartmental methods. Analysis of variance with a mixed-effect model was performed for treatment and gender comparisons. In 27 evaluable subjects, the regimens provided bioequivalent ABC daily areas under the concentration-time curve from 0 to 24 h (AUC0-24) and comparable CBV-TP concentrations at the end of the dosing interval (C τ). As expected, ABC QD resulted in 109% higher ABC maximum concentrations of drug in plasma (C max) than did ABC BID. ABC QD also resulted in 32% higher CBV-TP AUC0-24 and 99% higher CBV-TP C max than did ABC BID. Females had a 38% higher weight-adjusted ABC AUC0-24 and 81% higher weight-adjusted CBV-TP AUC0-24 than did males. Virologic suppression was maintained during regimen switch, and no tolerability differences between regimens were observed. In conclusion, this study showed that ABC 600 mg QD and ABC 300 mg BID regimens led to similar intracellular CBV-TP C τ values, thus providing pharmacokinetic support for the interchangeability of these two regimens. Women had higher intracellular CBV-TP exposure than did men.

scholarly journals Oral manifestations in human immunodeficiency virus infected patients

2010 ◽  
Vol 55 (1) ◽  
pp. 116 ◽  
Author(s):  
Sumit Sen ◽  
Sukanta Mandal ◽  
Sourav Bhattacharya ◽  
Saswati Halder ◽  
Parna Bhaumik
Keyword(s):  
Human Immunodeficiency Virus ◽  
Oral Manifestations ◽  
Immunodeficiency Virus

HIV Discrimination, Stigma, and Gender-Based Violence

2017 ◽  
Author(s):  
Antoine Douaihy ◽  
Neeta Shenai ◽  
Kimberly Clinebell ◽  
Mary Ann Cohen
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hiv Transmission ◽  
Negative Impact ◽  
Hiv Stigma ◽  
Gender Based Violence ◽  
Immunodeficiency Virus ◽  
Infectious Illness ◽  
Gender Based ◽  
And Gender ◽  
Hiv Discrimination

Stigma, discrimination, and gender-based violence complicate and perpetuate the human immunodeficiency virus (HIV) pandemic. Although remarkable strides have transformed AIDS from a rapidly fatal infectious illness to a chronic manageable illness, HIV-based stigma, discrimination, and gender-based violence, together known as AIDSism, still exist and have not been transformed in the same way as the illness itself. These barriers continue to have a negative impact on prevention and testing as well as in engagement, retention, and adherence to care. This chapter explores the role that clinicians can play in recognizing and ameliorating HIV stigma, discrimination, and gender-based violence in order to diminish both suffering and HIV transmission and lead to compassionate and competent approaches to care.

Sign in / Sign up

Export Citation Format

Share Document